Advertisement

Topics

Neurogene, Inc. Company Profile

08:35 EST 19th February 2019 | BioPortfolio

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technologies to develop treatments for diseases not well served by gene therapy. For more information, visit www.neurogene.com.


News Articles [10 Associated News Articles listed on BioPortfolio]

Neurogene Names Stuart Cobb Chief Scientific Officer

Gene therapy developer Neurogene has appointed Stuart Cobb to serve as its chief scientific officer. Cobb is currently a scientist at the University of Edinburgh. Neurogene says he will split his time...

Neurogene Emerges with $68M to Advance Gene Therapies to the Clinic

Neurogene is breaking into gene therapy with $68.5 million in new funding to support research on experimental treatments for rare, genetic brain disorders, the first of which could start human testing...

Neurogene raises $68.5m financing to advance several programs in neurological diseases

Neurogene said investors included Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund. The proceeds will support a product pipeli...

Neurogene raises funds to support gene therapy development

Neurogene has secured funding during a Series A financing round to advance the development of its gene therapy candidates intended...Read More... The post Neurogene raises funds to support gene therap...

Funding round pulls in $68.5M for Neurogene

A round of Series A funding raised $68.5 million for Neurogene.  -More- 

Neurogene Raises $68.5 Million in Series A Financing to Advance Multiple Programs in Devastating Neurological Diseases

Proceeds support a product pipeline with multiple AAV-based gene therapies with disease-modifying potential and creation of a company-owned AAV manufacturing facility ...

Neurogene raises $68.5M series A for neurological disease gene therapies

Neurogene Appoints Stuart Cobb, Ph.D., as Chief Scientific Officer

- Appointment bolsters Neurogene’s mission to bring life-changing therapies to patients with rare neurological disorders - Neurogene, Inc., a new company fo...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Neurogene, Inc.

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advo...

More Information about "Neurogene, Inc." on BioPortfolio

We have published hundreds of Neurogene, Inc. news stories on BioPortfolio along with dozens of Neurogene, Inc. Clinical Trials and PubMed Articles about Neurogene, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurogene, Inc. Companies in our database. You can also find out about relevant Neurogene, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record